A Biopsychosocial-Based Multimodal Approach to Reducing the Risk of Delirium in ICU
NCT ID: NCT07249619
Last Updated: 2025-11-25
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
NA
34 participants
INTERVENTIONAL
2026-01-02
2028-01-02
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Patients will be divided into two groups. One group will receive only the routine treatment program recommended by international guidelines (medical, enviromental adjustment and face-to-face interview etc.), while the other group will receive body awareness therapy addition to routine interventions.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
PREdiction of DELIRium in Medical ICU Patients
NCT04218461
Automating Delirium Severity in the ICU
NCT06172491
PRE-DELIRIC Prediction Model Plus SMART Care to Reduce the Incidence of Delirium in ICU Patients
NCT06279390
Delirium Prevention Guideline for Intensive Care Patients
NCT06403410
Prevention of Delirium in ICU Using Multimodal Interventions
NCT05950958
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Routine Treatment
A treatment program will be implemented in line with the recommendations of international guidelines for the treatment of delirium.
Routine Therapy (Medical, environmental accodamation, face-to-face commucation)
In the treatment of delirium, a treatment program will be implemented in line with the recommendations of international guidelines.
ICU.Delibma
In addition to the treatment program implemented in line with the recommendations of international guidelines for the treatment of delirium, "Basic Body Awareness Therapy" and "Communication Program" will be applied.
Routine Therapy (Medical, environmental accodamation, face-to-face commucation)
In the treatment of delirium, a treatment program will be implemented in line with the recommendations of international guidelines.
Biopsychosocial-Based Multimodal Approach
Delirium treatment will be implemented in accordance with international guidelines. Additionally, a basic body awareness therapy and communication program will be implemented.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Routine Therapy (Medical, environmental accodamation, face-to-face commucation)
In the treatment of delirium, a treatment program will be implemented in line with the recommendations of international guidelines.
Biopsychosocial-Based Multimodal Approach
Delirium treatment will be implemented in accordance with international guidelines. Additionally, a basic body awareness therapy and communication program will be implemented.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients scheduled for intensive care for at least 15 days due to SAH, unruptured intracranial aneurysm, and/or Arterovenous Malformation,
* Those with a Mini Mental State Examination score of \> 24,
* Those with a Glasgow Coma Score of 15,
* Those with motor function in at least one extremity,
* Those with pain \< 5/10 (according to the NRS)
Exclusion Criteria
* Patients who developed septic shock and MODS;
* Patients requiring endotrachial intubation and mechanical ventilation due to ARDS;
* Those requiring vasopressors such as NE at a rate of \>0.25 mcg/kg/min;
* Terminal cancer cases;
* Patients with advanced chronic heart and lung failure and COPD;
* Those with a METS (exercise capacity) of \<4;
* Those with a history of dementia, Alzheimer's disease, or psychiatric illness;
* Those with vision, hearing, or speech problems that would interfere with communication;
* Those with a history of epilepsy;
18 Years
85 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Emre Şenocak
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Emre Şenocak
Assoc. Prof. Dr.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Hülya Ulusoy, PhD
Role: PRINCIPAL_INVESTIGATOR
Karadeniz Technical University
Nurel Ertürk, PhD
Role: PRINCIPAL_INVESTIGATOR
Tarsus University
Gizem Ergün, Physiotherapist
Role: PRINCIPAL_INVESTIGATOR
Karadeniz Technical University
Neslihan Hatınoğlu, PhD
Role: PRINCIPAL_INVESTIGATOR
Karadeniz Technical University
Müge Koşucu, PhD
Role: PRINCIPAL_INVESTIGATOR
Karadeniz Technical University
Duygu Yıldırım, Phyiotherapist
Role: PRINCIPAL_INVESTIGATOR
Trabzon Kanuni Training and Research Hospital
Arzu Erden Güner, PhD
Role: STUDY_CHAIR
Karadeniz Technical University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Karadeniz Technical University, Farabi Hospital
Trabzon, , Turkey (Türkiye)
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2024/6
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.